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to infection
Interleukin 1 (IL 1) is a potent enhancer of nonspecific resistance to infection in mice. 
Since IL1 also induces interleukin 6 (IL6), we tested the hypothesis that IL 6 medi­
ates the effect of IL1 on nonspecific resistance. In a lethal Pseudomonas aeruginosa 
infection in granulocytopenic mice, in which 80 ng of recombinant human IL l a  pro­
tects against death, IL 6 appeared to be much less effective. Dosages of 8 ng, 80 ng 
and 320 ng IL 6 did not differ from the control, whereas 800 ng had a marginal 
protective effect (0.05 <  p <  0.1). IL1 and IL 6 did not potentiate each other in ani­
mals treated with suboptimal dosages of both cytokines. Numbers of bacteria cultured 
from the blood, thigh muscle, liver, spleen, and kidney were similar in animals treated 
with 800 ng IL 6 and in control animals, arguing against activation of microbicidal 
mechanisms. The serum concentration profile of IL 6 after an i.p. injection of 80 ng 
IL1 was similar to that after 80 ng IL 6 i.p. Only minute amounts of IL1 were 
detected in serum after an i.p. injection of IL 6. Taken these data together, it appears 
that increased resistance to infection induced by IL1 is not mediated by IL 6.
I Introduction
Recently, we have reported the beneficial effect of recombi­
nant interleukin 1 (rIL 1) on survival of granulocytopenic mice 
with a lethal Pseudomonas aeruginosa infection [1]. In this 
study, we found protection with a single low dosage of IL1(3. 
Although we could demonstrate that protection was not due to 
a direct antimicrobial effect of IL 1, to granulocytes or to acti­
vation of macrophages, we were unable to elucidate the 
mechanisms of protection against lethal P. aeruginosa infec­
tion. One hypothesis was that treatment with IL1 protected 
against the lethal effects of the lipopolysaccharide (LPS) or 
other toxins of P. aeruginosa. In a subsequent study, in which 
the effect of IL 1 on a candidal infection in neutropenic mice 
was investigated, we could demonstrate that the effect of IL 1 
on survival is not limited to Gram-negative infection [2].
IL6 is a 26-kDa cytokine, which is produced by mononuclear 
phagocytes, fibroblasts and a variety of other types of cells 
¡3-5]. This factor has been described as interferon-(32 [6], 
hybridoma (plasmocytoma) growth factor [7-9], B cell- 
stimulating factor 2 (BSF-2) [10] and hepatocyte-stimulating 
factor [11]. Since IL1 is a potent inducer of IL 6, the latter 
could be responsible for the enhanced survival of animals 
treated with IL 1, e.g., by inducing a hepatic acute-phase pro­
tein. Therefore, we have compared the effects of IL 6 and IL 1 
on survival of lethally infected mice. In addition, we have 
investigated the kinetics of injected IL 6 and IL1, and the 
mutual induction of these cytokines in vivo.
[I 7221]
Correspondence: Jos W. M. Van der Meer, Department of Internal 
Medicine, University Hospital St. Radboud, Nijmegen, The Nether­
lands
Abbreviations: (r)IL: (Recombinant) interleukin LPS: Lipopoly­
saccharide
2 Materials and methods
2.1 Mice
Female, 25 g Swiss Webster mice (Broekman, Someren, The 
Netherlands), were fed standard laboratory chow and water ad 
libitum.
2.2 IL
Human recombinant I L l a  (rIL la) ,  which was kindly pro­
vided by Dr. Peter Lomedico, Hoffmann-La Roche, Nutley, 
NJ, was used in the majority of the experiments. rIL 1(3 (kindly 
provided by Dr. Alan Shaw, Biogen/Glaxo, Geneva, Switzer­
land) was also used. These IL1 preparations contained 
< 30  pg lipopolysaccharide (LPS) per mg of protein. Human 
rIL 6, containing < 3  pg LPS/(ig of protein was produced as 
published elsewhere [8].
IL1 and IL 6 were given as a single i.p. injection in 2% (v/v) 
normal mouse serum in 0.1 ml pyrogen-free saline. Control 
mice received heat-inactivated IL1 (100°C for 20 min).
2.3 Infection model
Mice were rendered granulocytopenic (<0.5 x 109 granulo­
cytes per liter) by means of two i.p. injections of cyclophos­
phamide (Bristol Myers, Syracuse, NY), 150 and 100 mg/kg of 
body weight, respectively, 4 days and 1 day before the inocu­
lation of the microorganism. Approximately 2 x 107 
Pseudomonas aeruginosa (27853, ATCC, Rockville, MD) 
were injected into the left thigh muscle. Two doses of gen- 
tamycin (Lyomed Inc., Rosemont, IL), 120 mg/kg, were given 
s.c., 6 and 23 h post infection [1]. The mice in each cage were 
randomized to receive either IL 1, IL 6 or heat-inactivated 
IL 1, 24 h before the inoculation of bacteria. Survival was
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over a period of at least 48 h. Survival curves were analyzed 
using the Kaplan Meier log rank test [12].
2.4 Clearance of bacteria
Twenty-four hours after the injection of P. aeruginosa, six 
mice treated with IL 6 and six control mice were killed by C 0 2 
asphyxia. Immediately after death, blood cultures were taken 
by cardiac puncture, and the muscles of the left thigh (the site 
of inoculation of the bacteria), the spleen, the kidney and the 
liver were removed aseptically, weighed and homogenized in 
sterile saline in a tissue grinder. To bring the counts into the 
optimal range for reading, samples of thigh muscle were 
diluted 1 : 104 and other samples were diluted 1 : 1 0  in sterile 
saline. The suspensions were then plated on sterile DST agar 
(Oxoid, Ltd., Basingstoke, GB) in tenfold dilutions After 
overnight incubation at 37 °C the number of colonies was 
counted.
2.5 Pharmacokinetics of rIL 6 and rIL 1, and induction of IL 6 
by IL 1
At various time points after an i.p. injection of 80 ng of IL 6, 
three mice were killed by C 0 2 asphyxia. Immediately after 
death blood was taken by cardiac puncture. The IL 6 concen­
trations in the sera obtained were measured using the B-9 cell 
line [5], and IL1 concentrations were measured using 
D10.G4.1 cells [13], the D10(N4)M subclone; both assays 
have been described in detail [14]. Similarly, serum concentra­
tions of IL 6 and IL 1 were measured after an i.p. injection of 
80 ng IL l a  in mice.
3 Results
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Figure 1. The effect of IL l a  and of IL 6 treatment on the survival of 
granulocytopenic mice with a P. aeruginosa infection. The cytokines 
were given as single i.p. injections 24 h before infection. Control mice 
received heat-inactivated IL 1 (100°C for 20 min). Only the difference 
in survival between animals treated with IL1 is significant (p<0.01). 
Each group consisted of 20 mice.
3.1 Survival of mice
3.3 Pharmacokinetics of rIL6 and induction of IL6 by IL1
The kinetics of 80 ng rIL 6 injected i.p. into mice (Fig. 4A) is 
remarkably similar to that of IL 6 induced by an i.p. injection 
of 80 ng r I L la  (Fig. 4B), although the maximal IL 6 concen­
tration after the IL 6 injection precedes that induced by IL1. 
In contrast, the serum concentrations of IL 1 after injection of 
IL 6 are barely measurable (Fig. 4A), whereas IL1 is readily 
measurable after injection of IL1 (Fig. 4B).
Human rIL la ,  given as a single i.p. injection of 80 ng (~  3 |ig/ 
kg) 24 h before infection, improved the survival of neu­
tropenic mice with a lethal P. aeruginosa infection significantly 
( X 2 = 6.8; p <  0 .01) compared to control mice that received 
heat-inactivated IL1 (Fig. 1). r IL 6 was much less effective 
than IL1 in these protection experiments (Fig. 1). Even the 
effect of 800 ng IL 6 was not significantly different from the 
control (x2 = 3.0; 0.05 <  p <  0.1); dosages of 320 ng, 80 ng and
8 ng did not differ from the control.
To investigate whether IL1 and IL 6 would potentiate each 
other, suboptimal dosages of both cytokines (8 ng and 80 ng, 
respectively) were injected either alone or in combination 
(Fig. 2). No potentiation was detected; if anything, there was 
slight, albeit not significant antagonism between IL 1 and IL 6.
3.2 Clearance of P. aeruginosa
No differences in the numbers of bacteria in blood and tissues 
were found between mice treated with 800 ng IL 6 or control 
mice 24 h after an i.m. injection of 2 x 107 P. aeruginosa 
(Fig. 3). When the data were expressed as number of microor­
ganisms per gram of tissue rather than per organ, the data 
from two groups also did not differ.
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Figure 2. The effect of 8 ng I L l a  and 80 ng IL 6 injected i.p. 24 h 
before infection, either alone or in combination, on survival of lethally 
infected mice. There is no potentiation of IL1 and IL 6. Only the 
difference between survival with 8 ng IL 1 and that of the control mice 
is significant at p <  0.025. Each group consisted of 22 mice.
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Figure 3. Counts of colonies of P. aeruginosa in the blood and organs 
of granulocytopenic mice, 24 h after inoculation of 2 x 107 cfu in the 
high muscle. Mice received either 800 ng IL 6 (stippled bars) or heat- 
inactivated IL1 (hatched bars) 24 h before inoculation. Each bar 
represents the mean ± SE of six mice.
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Figure 4. Serum concentration profiles of IL 6 (□) and IL 1 (■) after 
i.p. injection of 80 ng IL 6 (A) or 80 ng I L l a  (B). Each data point 
represents mean of serum samples from three mice; bars represent SE.
4 Discussion
In the present study, we have investigated the hypothesis that 
IL6 is the central mediator of IL 1-induced protection against 
lethal bacterial infection in mice. The experiments show that 
IL6 is 10-100 times less potent than IL 1 in protecting mice. If 
IL1 induced a large amount of IL 6 in vivo ,  these results still 
would not rule out an IL 6-mediated pathway. Although we 
could indeed demonstrate that IL 1 is a potent inducer of IL 6 
in mice, the serum concentrations of IL 6 after an i.p. injection 
of 80 ng IL 1 are quite similar to those after an injection of the 
(barely protective) 80 ng dose of IL 6 i.p. Taking these data 
together, the hypothesis mentioned above has to be refuted.
The next question we addressed was whether IL1 and IL 6 
would potentiate each other. Using suboptimal dosages of 
each cytokine, we could not detect any synergism. However, 
the 800-ng dose of IL 6 had some protective effect, and these 
results are reminiscent of experiments with tumor necrosis fac­
tor (TNF), in which a similar high dose was needed to find 
some protection [15, 16]. Since we observed that IL 6 does 
induce minute amounts to IL1 in vivo ,  the protection by IL 6 
might be mediated via IL1.
The actual mechanism responsible for increase in survival 
induced by IL1, IL 6 and TNF remains unclear. In our previ­
ous studies direct antimicrobial effects of IL 1 were ruled out 
in vitro [1, 2\. Since the mice were profoundly granulocy­
topenic in those studies, an effect of IL 1 on the neutrophils 
was considered unlikely. Also, the beneficial effects of IL 1 on 
hematopoiesis [17] were not demonstrated in our short-term 
experiments [1, 2]. In the IL1 studies, no effect of IL1 on 
macrophages could be demonstrated [1]. The most convincing 
argument against an effect on microbicidal function of mac­
rophages, however, came from the microbial clearance data, 
which failed to demonstrate a difference between IL 1-treated 
and control mice [1, 2, 15]. In the present study, we have 
obtained similar results with IL 6, i.e. ,  the numbers of bacteria 
in the blood and the various organs were similar in IL 1-treated 
mice and control mice.
It is assumed that cytokines like TNF and IL 1 contribute to 
death from infection [18-20]. It could well be that early treat­
ment with IL 1, and to a much lesser extent with IL 6, reduces 
the lethal effects of these cytokines. This protection could be 
produced by down-regulation of receptors for these cytokines 
in the lethal phase. The down-regulation of TNF receptors by 
IL 1 treatment, which has recently been described to occur in 
vitro ,  is in agreement with this concept [21 ].
In conclusion, whatever the mechanisms of IL 1-induced pro­
tection against death due to lethal infection may be, IL 6 does 
not appear to be a critical intermediate cytokine.
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